IL-17

CD19 CAR T Cell Therapy in SLE (9.16.2022)

Jack Cush, MD

2 years 3 months ago

Dr. Jack Cush reviews the news, journal reports, ACR and FDA announcements from the past week on RheumNow.com First In Class, TYK2 Inhibitor FDA Approved for Psoriasis 2022 New ACR Guidance…

EULAR 2022 – Day 4 Report

Jack Cush, MD

2 years 6 months ago

Bags are packed, ready to go, but wait there’s more abstracts to show. The big news today were the “late breaking” abstracts. This is usually a favorite session of many as this is where the newest…

EULAR 2022 - Day 4 Faculty Panel Recap

2 years 6 months ago

Malignancy risk on b/tsDMARDs in patients with prior malignancy history

Eric Dein, MD

2 years 6 months ago

For autoimmune patients with a history of malignancy, the initiation of biologic or targeted synthetic disease modifying agents (bDMARD/tsDMARDs) may provoke concern. While data for biologic…

Key Psoriatic Arthritis topics and updates at EULAR 2022

Antoni Chan, MD, PhD

2 years 6 months ago

At EULAR 2022, I have been looking at topics and presentations in psoriatic arthritis (PsA). How do PsA patients do on csDMARDs and is the time to switch or escalate to biologics the same as…

Robert B Chao, MD doctorRBC

2 years 6 months ago

Bimekizumab: IL-17A and F inhibitor for tx of PsA - BE OPTIMAL trial reached primary endpoint: ACR50 44% vs. placebo Efficacy as early as 2 weeks No MACE, uveitis, IBD, deaths @RheumNow #EULAR2022 ABST#LB0001 https://t.co/sHRRwLlChi

Robert B Chao, MD doctorRBC

2 years 6 months ago

In vitro study shows Upadacitinib inhibits enthesis T cell derived TNFa and IL-17A, disrupting the prominent IL-23/IL-17/TNFa axis driving SpA. @RheumNow #EULAR2022 ABST#POS0331 https://t.co/pNL3Zlgmt7

TheDaoIndex KDAO2011

2 years 6 months ago

Phase 3 compared Bimekizumab to PCB and Humira; it met all endpoints for PsA; the drug inhibits both IL17F & IL-17A. Safety signal: increase fungal (candidal) infx #EULAR2022 LB0001 @rheumnow https://t.co/MJJwj44YgU

Richard Conway RichardPAConway

2 years 6 months ago

McInnes @IainBMcInnes1 et al. Bimekizumab (IL17A/Fi) in PsA. BE OPTIMAL 852 patient RCT vs PBO vs ADA. Looks same for joints, better for skin than ADA (not stat sig) @RheumNow #EULAR2022 LB0001 https://t.co/oKEHJE3tGn https://t.co/H7nPnbEWUB

EULAR Abstract Archive

Dr. Antoni Chan synovialjoints

2 years 6 months ago

Bimekizumab (BKZ) vs PBO at 16 week BE COMPLETE for PsA with inadequate response to TNFi ACR50 44% vs 7%,PASI90 69% vs 7%, ACR20 67% vs 16%, ACR70 27% vs 0.8%, PASI 100 60% vs 5%, MDA 44% vs 6%, no new safety signals #EULAR2022 @RheumNow OP0255 Merola et al https://t.co/riU2sIXGs9